Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 15/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14539452 | 0.88 | GHSR (0.59) | GHSRHTR5ASLC2A1POLB | |
| SCHEMBL13694055 | 0.84 | GHSR (0.50) | GHSRHTR5APOLB | |
| SCHEMBL13693961 | 0.84 | GHSR (0.55) | GHSRPOLB | |
| SCHEMBL13693966 | 0.83 | GHSR (0.51) | GHSRHTR5APOLB | |
| SCHEMBL13693960 | 0.83 | GHSR (0.51) | GHSRHTR5APOLB | |
| SCHEMBL13693964 | 0.83 | GHSR (0.54) | GHSRHTR5APOLB | |
| SCHEMBL13694064 | 0.82 | GHSR (0.50) | GHSRHTR5APOLB | |
| SCHEMBL13694045 | 0.82 | GHSR (0.50) | GHSRHTR5APOLB | |
| SCHEMBL12133578 | 0.82 | GHSR (0.50) | GHSRHTR5APOLB | |
| SCHEMBL13694071 | 0.82 | GHSR (0.50) | GHSRHTR5APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883627-B1 | BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| US-8575113-B2 | BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2013-11-05 | — | — | US | disclosed |
| US-8575113-B2 | BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2013-11-05 | — | — | US | disclosed |
| US-20120141496-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2012-06-07 | — | — | US | disclosed |
| US-20120141496-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2012-06-07 | — | — | US | disclosed |
| US-8063095-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | PHARMASCIENCE INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-8063095-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | PHARMASCIENCE INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-7795298-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2010-09-14 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| WO-2007048224-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| WO-2006122408-A9 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | GHSR 2189/4885HTR5A 3980/4885SLC2A1 3127/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | GHSR 2189/4885HTR5A 3980/4885SLC2A1 3127/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | GHSR 124/4885HTR5A 3090/4885SLC2A1 3321/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | GHSR 1696/4885HTR5A 3893/4885SLC2A1 2772/4885 |
| US-20120141496-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | GHSR 2558/4885HTR5A 3719/4885SLC2A1 3547/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | GHSR 3979/4885HTR5A 3889/4885SLC2A1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.